Skip to main content

Table 2 Trial performance

From: Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trial

  Total UA/NSTEMI PCI CABG
Enrolment     
   Projected 9 000 40-50% 20-35% 10-20%
   Actual* 11 590 45% 30% 25%
Event rate     
   Projected 13.12% 10-15% 10-15% 20-25%
   Actual 12.95% 12.72% 10.91% 15.78%
  1. *The total number of patients recruited was readjusted followed a blinded interim analysis that showed an event rate slightly lower than expected.